464 related articles for article (PubMed ID: 8658369)
21. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.
Colice GL
Am J Med; 1996 Jan; 100(1A):11S-18S. PubMed ID: 8610712
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease.
Patakas D; Andreadis D; Mavrofridis E; Argyropoulou P
Respir Med; 1998 Sep; 92(9):1116-21. PubMed ID: 9926165
[TBL] [Abstract][Full Text] [Related]
23. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.
Chest; 1994 May; 105(5):1411-9. PubMed ID: 8181328
[TBL] [Abstract][Full Text] [Related]
24. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
Campbell S
Arch Intern Med; 1999 Jan; 159(2):156-60. PubMed ID: 9927098
[TBL] [Abstract][Full Text] [Related]
25. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.
O'Donnell DE; Lam M; Webb KA
Am J Respir Crit Care Med; 1999 Aug; 160(2):542-9. PubMed ID: 10430726
[TBL] [Abstract][Full Text] [Related]
26. Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled beta 2-agonist in the treatment of stable COPD?
Nishimura K; Koyama H; Ikeda A; Izumi T
Chest; 1993 Jul; 104(1):179-84. PubMed ID: 8325065
[TBL] [Abstract][Full Text] [Related]
27. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
Chhabra SK; Vijayan VK; Vasu T
Indian J Chest Dis Allied Sci; 2006; 48(2):97-102. PubMed ID: 16696522
[TBL] [Abstract][Full Text] [Related]
28. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD.
Sichletidis L; Kottakis J; Marcou S; Constantinidis TC; Antoniades A
Int J Clin Pract; 1999; 53(3):185-8. PubMed ID: 10665129
[TBL] [Abstract][Full Text] [Related]
29. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD.
Karpel JP; Kotch A; Zinny M; Pesin J; Alleyne W
Chest; 1994 Apr; 105(4):1089-94. PubMed ID: 8162730
[TBL] [Abstract][Full Text] [Related]
30. Dose-response comparison of ipratropium bromide from a metered-dose inhaler and by jet nebulisation.
Gomm SA; Keaney NP; Hunt LP; Allen SC; Stretton TB
Thorax; 1983 Apr; 38(4):297-301. PubMed ID: 6223402
[TBL] [Abstract][Full Text] [Related]
31. Anticholinergic versus beta 2-agonist on gas exchange in COPD: a comparative study in 15 patients.
Pillet O; Manier G; Castaing Y
Monaldi Arch Chest Dis; 1998 Feb; 53(1):3-8. PubMed ID: 9632900
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease.
Matera MG; Cazzola M; Vinciguerra A; Di Perna F; Calderaro F; Caputi M; Rossi F
Pulm Pharmacol; 1995 Dec; 8(6):267-71. PubMed ID: 8819181
[TBL] [Abstract][Full Text] [Related]
33. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD.
LeDoux EJ; Morris JF; Temple WP; Duncan C
Chest; 1989 May; 95(5):1013-6. PubMed ID: 2523291
[TBL] [Abstract][Full Text] [Related]
34. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease.
Cazzola M; Matera MG; Di Perna F; Calderaro F; Califano C; Vinciguerra A
Respir Med; 1998 Feb; 92(2):354-7. PubMed ID: 9616538
[TBL] [Abstract][Full Text] [Related]
35. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.
Bleecker ER; Britt EJ
Am J Med; 1991 Oct; 91(4A):24S-27S. PubMed ID: 1835291
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.
Maesen FP; Greefhorst LP; Smeets JJ; Wald FD; Cornelissen PJ
Respiration; 1997; 64(4):273-80. PubMed ID: 9257362
[TBL] [Abstract][Full Text] [Related]
38. The role of domiciliary nebulizers in managing patients with severe COPD.
Eiser N; Angus K; McHale S
Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD.
Karpel JP; Pesin J; Greenberg D; Gentry E
Chest; 1990 Oct; 98(4):835-9. PubMed ID: 2145136
[TBL] [Abstract][Full Text] [Related]
40. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease.
Imhof E; Elsasser S; Karrer W; Grossenbacher M; Emmons R; Perruchoud AP
Respiration; 1993; 60(2):84-8. PubMed ID: 8341859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
